Shots: The FDA’s approval is based on P-III INBUILD study assessing Ofev (150mg, bid) vs PBO in 663 patients with chronic fibrosing ILDs with a progressive phenotype for 52wks. at […]readmore
Tags : Chronic Fibrosing ILDs
Shots: The BT designation is based on P-III INBUILD study results assessing OFEV vs PBO in patients with chronic fibrosing interstitial lung disease (ILDs) with signs of progression for 52 […]readmore